TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement in Incontinence Symptom Severity Index (ISSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Number of Micturitions Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Number of Incontinence Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in NF-KB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Completion of mammogram screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Pap test screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daily dose of REKOVELLE® in micrograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of days of treatment with REKOVELLE®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day of REKOVELLE® stimulation start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration time in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall confidence level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Concentration of serum S100 β protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants with Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function Tests (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary Function Tests (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of in-hospital patients who survive the injury
Endpoint domain: Mortality/survival
Primary endpoint: Patients' Evaluation of Quality of Care
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fissure sealant loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Are Able to Receive 6 Cycles of Intraperitoneal Cisplatin Chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of Respiratory Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the serum concentration versus time curve (AUC) of Amoxicillin/Clavulanic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration versus time curve (AUC) of Cefuroxime
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral ulcers
Endpoint domain: Adverse events/effects
Primary endpoint: GI tract disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: hematology
Endpoint domain: Adverse events/effects
Primary endpoint: renal hepatic AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Non-Relapse Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Catheter-Related Blood Stream Infection (CRBSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Amount of [14C] Radiolabel Excreted in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Amount of [14C] Radiolabel Excreted in Feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hayfever symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of hayfever symptom relieving medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive State
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of ACR 20 Criteria Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic Comfort and Utility
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Boost Challenge Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation during euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain activation during hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total number of asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerability and safety of novel treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity of novel treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Time to colorectal cancer relapse
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of study recruitment and retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional abilities of children and adolescents affected by cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number Of Participants Who Experienced Treatment-related Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Curve Over Dosing Interval τ at Steady State (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of the Analyte in Plasma at Steady State (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose Limiting Toxicity Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of vision acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of cycloplegic refractive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Ceramides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in patient-reported oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F-FDOPA PET activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRI contrast enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: high- or low-grade glioma biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: infant's pain level before vaccine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant's pain level during vaccine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant's pain level after vaccine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of doppler-detected cerebral micro emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Venous obstruction more than 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Post-transfusion Platelet Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 30 Minute-6 Hour Difference in Platelet Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improved side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of single dose radio labeled MORAb-028
Endpoint domain: Adverse events/effects
Primary endpoint: Change in glucose during oral glucose tolerance test (oGTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acceptability ratings of the program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of postoperative bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severe complication
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Percent Change From Baseline in Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Percent Change From Baseline in Peak Expiratory Flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: clinically significant portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: percentage of time with intragastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Physical function performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach defined physical therapy milestones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Protective Levels of Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0-∞ (area under the concentration-time curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of drug in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of invasive pneumococcal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of study follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of patients with 20% improvement of CIVIC scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in beta-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in ketone levels (breath acetone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Adverse Events Grade 3 or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects achieving a ≥20% improvement in disease severity (ACR20 CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Disease Activity Score 28 (DAS28-4[CRP])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Revised-UCLA (R-UCLA) Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Red blood cell allo-antibody formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immune cell percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Leeds Sleep Evaluation Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Instantaneous Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under plasma concentration-time curve (AUC) of AZD5718
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed maximum plasma concentration (Cmax) of AZD5718
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed plasma concentration at 24 hours post dose (C24) of AZD5718
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of BD glucan in peritoneal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative and positive predictive value of BD glucan in peritoneal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of new self-reported general eye or dysphotopsia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Baseline NGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracavernous NGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmatic NGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain assessed with the Visual Analogic Scale Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain assessed with the Pain Disability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain assessed with the Fibromyalgia Impact Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal elimination half-life (t1/2el)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in uterine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of subjects that achieved amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Episodes of Symptomatic UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood Glucose Serum Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of severity of placenta accreta spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Alcohol Approach Bias
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of loss of esophagitis symptom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Study Drug-Related Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Perfusion Defect Percentage (PDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of concordance between ventilation and perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface lustre of dental restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staining restoration surface and restoration margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture of material and retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported Adherence to Triple Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Discrimination between Malignant and Benign Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: patient weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to re-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time to rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intact parathyroid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the drug concentration curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of MEDI0382
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TILs characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum concentration of 25(OH) D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physiological changes in heart rate and blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dose Limiting Toxicity level
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain (6 to <36 Months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain (3 to <9 Years)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain (9 to <18 Years)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achieving Seroconversion Against A/H5N1 Strain (6 to <36 Months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Buccal soft tissue profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor symptom improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin sensitization reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with low pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 12 Hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 24 Hours
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post insertion failure rates
Endpoint domain: Adverse events/effects
Primary endpoint: Overall utility
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Eyes With Posterior Capsule Opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Western Ontario and Mc Master University OA Index (WOMAC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Development Quotient (DQ) score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive clinical parameters for aggressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sun burns
Endpoint domain: Adverse events/effects
Primary endpoint: skin self-exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: benign or malignance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The incidence of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: GI mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 3 point major adverse cardiovascular events (4P-MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-incision heart rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-incision blood pressure increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-incision bispectral index increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-incision movement occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % time spent above 8mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infusional toxicity of ex vivo expanded allogeneic CIK cells
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Graft-versus-Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of expanded CIK cells
Endpoint domain: Physiological/clinical
Primary endpoint: Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of Plasma Presepsin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incident rate of HBV DNA negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of hypertensive leg ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of swallow of Tsururinko Quickly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Peripheral Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of heterotopic ossification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV/HCV injection risk behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of fMRI analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DPA-RA invasive blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of TV005 and rDEN3Δ30-related adverse events
Endpoint domain: Adverse events/effects